Novo nordisk to acquire inversago pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

BagsvÆrd, denmark and montreal, canada, 1 0 august 2023 – novo nordisk a/s and inversago pharma today announced that novo nordisk has agreed to acquire inversago for up to 1.075 billion us dollars in cash if certain development and commercial milestones are achieved. inversago pharma is a private, montreal-based developer of cb1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
NVO Ratings Summary
NVO Quant Ranking